Portable, On-Demand Biomolecular Manufacturing

Synthetic biology uses living cells as molecular foundries for the biosynthesis of drugs, therapeutic proteins, and other commodities. However, the need for specialized equipment and refrigeration for production and distribution poses a challenge for the delivery of these technologies to the field and to low-resource areas. Here, we present a portable platform that provides the means for on-site, on-demand manufacturing of therapeutics and biomolecules. This flexible system is based on reaction pellets composed of freeze-dried, cell-free transcription and translation machinery, which can be easily hydrated and utilized for biosynthesis through the addition of DNA encoding the desired output. We demonstrate this approach with the manufacture and functional validation of antimicrobial peptides and vaccines and present combinatorial methods for the production of antibody conjugates and small molecules. This synthetic biology platform resolves important practical limitations in the production and distribution of therapeutics and molecular tools, both to the developed and developing world.

[1]  A. Kols,et al.  HPV vaccines: promise and challenges. , 2000 .

[2]  Michelle E. Hung,et al.  Designed Ankyrin Repeat Proteins ( DARPins ) : Binding Proteins for Research , Diagnostics , and Therapy , 2015 .

[3]  Carmen Méndez,et al.  Reevaluation of the Violacein Biosynthetic Pathway and its Relationship to Indolocarbazole Biosynthesis , 2006, Chembiochem : a European journal of chemical biology.

[4]  Vincent Noireaux,et al.  The All E. coli TX-TL Toolbox 2.0: A Platform for Cell-Free Synthetic Biology. , 2016, ACS synthetic biology.

[5]  G. Chang,et al.  In vitro nanobody discovery for integral membrane protein targets , 2014, Scientific Reports.

[6]  B. Zakeri,et al.  Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin , 2012, Proceedings of the National Academy of Sciences.

[7]  S. Y. Wong,et al.  On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system , 2016, Science.

[8]  M. Rajabibazl,et al.  Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes , 2013, Applied Microbiology and Biotechnology.

[9]  Bradley C. Bundy,et al.  Lyophilized Escherichia coli-based cell-free systems for robust, high-density, long-term storage. , 2014, BioTechniques.

[10]  A. Mimran,et al.  Efficacy of a Potential Trivalent Vaccine Based on Hc Fragments of Botulinum Toxins A, B, and E Produced in a Cell-Free Expression System , 2010, Clinical and Vaccine Immunology.

[11]  Yu Cao,et al.  An immunosuppressive antibody-drug conjugate. , 2015, Journal of the American Chemical Society.

[12]  J. Swartz,et al.  Development of cell‐free protein synthesis platforms for disulfide bonded proteins , 2008, Biotechnology and bioengineering.

[13]  Guillaume Lambert,et al.  Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components , 2016, Cell.

[14]  J. Collins,et al.  Programmable cells: interfacing natural and engineered gene networks. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Greenberg,et al.  Cell‐free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens , 2012, Biotechnology and bioengineering.

[16]  J. Tanha,et al.  Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain* , 2011, The Journal of Biological Chemistry.

[17]  V. Martin,et al.  Reconstitution of a 10-gene pathway for synthesis of the plant alkaloid dihydrosanguinarine in Saccharomyces cerevisiae , 2014, Nature Communications.

[18]  R. Gupta,et al.  Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Rappuoli,et al.  Differences in the immunogenicity of native and formalinized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. , 1997, Vaccine.

[20]  Timothy K Lu,et al.  Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care , 2016, Nature Communications.

[21]  Raffaella Fior,et al.  A cell‐free expression and purification process for rapid production of protein biologics , 2016, Biotechnology journal.

[22]  R. Hutubessy,et al.  Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. , 2008, Bulletin of the World Health Organization.

[23]  Ashty S Karim,et al.  A cell-free framework for rapid biosynthetic pathway prototyping and enzyme discovery. , 2016, Metabolic engineering.

[24]  M. Castanho,et al.  From antimicrobial to anticancer peptides. A review , 2013, Front. Microbiol..

[25]  B. Vikram,et al.  Diphtheria Re-emergence: Problems Faced by Developing Countries , 2013, Indian Journal of Otolaryngology and Head & Neck Surgery.

[26]  Zsofia Botyanszki,et al.  Engineered catalytic biofilms: Site‐specific enzyme immobilization onto E. coli curli nanofibers , 2015, Biotechnology and bioengineering.

[27]  A. Spirin,et al.  Functional antibody production using cell-free translation: Effects of protein disulfide isomerase and chaperones , 1997, Nature Biotechnology.

[28]  Pamela A Silver,et al.  Efficient solar-to-fuels production from a hybrid microbial–water-splitting catalyst system , 2015, Proceedings of the National Academy of Sciences.

[29]  C. Barrios,et al.  Access to cancer medications in low- and middle-income countries , 2013, Nature Reviews Clinical Oncology.

[30]  James J. Collins,et al.  Paper-Based Synthetic Gene Networks , 2014, Cell.

[31]  I. Frazer,et al.  Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model , 2010, PloS one.

[32]  Xiaolian Gao,et al.  Expression of family 3 cellulose-binding module (CBM3) as an affinity tag for recombinant proteins in yeast , 2011, Applied Microbiology and Biotechnology.

[33]  D. Bernstein,et al.  Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial , 2014, Open forum infectious diseases.

[34]  Ashty S. Karim,et al.  Cell‐free metabolic engineering: Biomanufacturing beyond the cell , 2015, Biotechnology journal.

[35]  Jeff Hasty,et al.  Programmable probiotics for detection of cancer in urine , 2015, Science Translational Medicine.

[36]  R. Rappuoli,et al.  The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. , 1984, Nucleic acids research.

[37]  Bradley C. Bundy,et al.  Cell‐free protein synthesis of a cytotoxic cancer therapeutic: Onconase production and a just‐add‐water cell‐free system , 2016, Biotechnology journal.

[38]  Lee R Lynd,et al.  A transition from cellulose swelling to cellulose dissolution by o-phosphoric acid: evidence from enzymatic hydrolysis and supramolecular structure. , 2006, Biomacromolecules.

[39]  Vincent Noireaux,et al.  Synthesis of 2.3 mg/ml of protein with an all Escherichia coli cell-free transcription-translation system. , 2014, Biochimie.

[40]  P. S. Andersen,et al.  Novel antibody–antibiotic conjugate eliminates intracellular S. aureus , 2015, Nature.

[41]  Jim Swartz,et al.  Developing cell-free biology for industrial applications , 2006, Journal of Industrial Microbiology and Biotechnology.

[42]  H. Mainzer,et al.  Frequency and causes of vaccine wastage. , 2002, Vaccine.

[43]  Manmohan J. Singh,et al.  Acceptable levels of endotoxin in vaccine formulations during preclinical research. , 2011, Journal of pharmaceutical sciences.

[44]  R. Kontermann,et al.  Dual targeting strategies with bispecific antibodies , 2012, mAbs.

[45]  P. Wolf,et al.  Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. , 2009, International journal of medical microbiology : IJMM.

[46]  A. Palmenberg.  In vitro synthesis and assembly of picornaviral capsid intermediate structures , 1982, Journal of virology.

[47]  S. Joshi,et al.  Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. , 2014, Biologicals : journal of the International Association of Biological Standardization.

[48]  A. Desmyter,et al.  Camelid nanobodies: killing two birds with one stone. , 2015, Current opinion in structural biology.

[49]  H. Komatsu.  [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[50]  A. Spirin,et al.  A continuous cell-free translation system capable of producing polypeptides in high yield. , 1988, Science.

[51]  Christopher T Walsh,et al.  In vitro biosynthesis of violacein from L-tryptophan by the enzymes VioA-E from Chromobacterium violaceum. , 2006, Biochemistry.

[52]  Richard M. Murray,et al.  Protocols for Implementing an Escherichia coli Based TX-TL Cell-Free Expression System for Synthetic Biology , 2013, Journal of visualized experiments : JoVE.

[53]  S. Levy,et al.  Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. , 2011, Protein expression and purification.

[54]  Zsofia Botyanszki,et al.  Programmable biofilm-based materials from engineered curli nanofibres , 2014, Nature Communications.

[55]  L J Millet,et al.  Modular microfluidics for point-of-care protein purifications. , 2015, Lab on a chip.

[56]  C. J. Murray,et al.  Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production—A New Approach for Shortening Protein Production Development Timelines , 2011, Biotechnology and bioengineering.

[57]  N. Haigwood,et al.  Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques , 2010, Nature Medicine.

[58]  Michael C. Jewett,et al.  High-throughput preparation methods of crude extract for robust cell-free protein synthesis , 2015, Scientific Reports.

[59]  V. Voynov,et al.  Therapeutic Proteins , 2012, Methods in Molecular Biology.

[60]  Vincent Noireaux,et al.  A vesicle bioreactor as a step toward an artificial cell assembly. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[61]  A. Spirin,et al.  Cell-free production of biologically active polypeptides: application to the synthesis of antibacterial peptide cecropin. , 2001, Protein expression and purification.

[62]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[63]  J. Collins,et al.  Toehold Switches: De-Novo-Designed Regulators of Gene Expression , 2014, Cell.

[64]  Yong-Chan Kwon,et al.  Ribosomal synthesis and in situ isolation of peptide molecules in a cell-free translation system. , 2010, Protein expression and purification.

[65]  J. Keasling,et al.  Synthetic and systems biology for microbial production of commodity chemicals , 2016, npj Systems Biology and Applications.

[66]  Dieter Söll,et al.  Evolution of translation machinery in recoded bacteria enables multi-site incorporation of nonstandard amino acids , 2015, Nature Biotechnology.